Volume
Open
Day's Low
Day's High
52 Wk Low
52 Wk High
Bid
Ask
EPS
PE Ratio
Shares
Market Cap
Dividend
Ex-Div Date
Yield
Do You Like Swing Trading?
Learn how we win with easy 3-5 day holds.
Be 'active' in the market while NOT being tied to your desk.
Be 'active' in the market while NOT being tied to your desk.
...
Health Technology » Pharmaceuticals Generic
| symbol | company | %chng | last | %short | avg$volume | |
|---|---|---|---|---|---|---|
| AGN | Allergan plc | 0.73% | 169.05 | 2.9% | $402.15m | |
| ZTS | Zoetis, Inc. Class A | 0.82% | 128.46 | 1.9% | $237.59m | |
| TEVA | Teva Pharmaceutical Industries Limited Sponsored ADR | -0.29% | 6.88 | 2.0% | $99.84m | |
| MYL | Mylan N.V. | 2.33% | 18.90 | 3.2% | $93.35m | |
| TXMD | TherapeuticsMD, Inc. | -0.39% | 3.85 | 24.9% | $12.72m | |
| RDY | Dr. Reddy's Laboratories Ltd. Sponsored ADR | 0.08% | 37.32 | 2.0% | $5.99m | |
| TARO | Taro Pharmaceutical Industries Ltd. | 2.14% | 76.04 | 6.5% | $3.73m | |
| LFVN | LifeVantage Corporation | -0.64% | 14.03 | 3.3% | $1.54m | |
| ABEO | Abeona Therapeutics, Inc. | 1.82% | 2.24 | 7.6% | $1.40m | |
| JAGX | Jaguar Animal Health, Inc. | -6.39% | 0.71 | 9.8% | $0.98m | |
| KIN | Kindred Biosciences, Inc. | 4.31% | 6.53 | 0.3% | $0.81m | |
| CPHI | China Pharma Holdings, Inc. | -4.20% | 0.25 | 0.1% | $0.02m |
Company Profile
BridgeBio Pharma, Inc. engages in developing transformative medicines to treat patients who suffer from mendelian diseases. Its pipeline of 15 development programs includes product candidates from early discovery to late-stage development. The firm develops BBP-265, an oral small molecule transthyretin for the treatment of TTR amyloidosis, including cardiomyopathy and polyneuropathy manifestations; infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor for the treatment of FGFR-driven cancers and in preclinical development for the treatment of achondroplasia; and BBP-631, a preclinical adeno-associated virus, gene transfer product candidate, for the treatment of congenital adrenal hyperplasia caused by 21OHD. The company was founded by Charles Homcy, Frank McCormick, Philip Reilly and Neil Kumar on May 17, 2019 and is headquartered in Palo Alto, CA.